Trial | NCT00884442  Report issue

Title

Nifedipine Bioavailability Study With Oral Single Doses Under Fasting and Fed Conditions
Randomized, Non-blind, 4-fold Crossover Study on Safety, Tolerability and Pharmacokinetics of Nifedipine After Single Oral Doses of Adalat® LA 60 mg or of a Marketed Generic Version of Nifedipine Retard 60 mg After an Overnight Fasting or Immediately After a High-fat American Breakfast in Healthy Male Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nifedipine ...

  • Study Participants

    28
The present study will be performed to investigate and to compare the in-vivo performance of the two investigational products Gen-nifedipine extended release, (previously referred to as Gen-Nifedipine XL (Genpharm ULC, Canada)) and Nifedipine(Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS) by comparing their pharmacokinetic parameters after oral single dose administrations in the fasted and fed state.
In the past, several attempts have been made to develop nifedipine formulations with pharmacokinetic characteristics similar to the unique characteristics of nifedipine GITS. A new extended release nifedipine tablet based on an osmotically active system for once a day administration has been registered under the trade name Gen-nifedipine extended release, (previously referred to as Gen-Nifedipine XL (Genpharm ULC, Canada)) in Canada.

According to the product monograph of Gen-nifedipine extended release, (previously referred to as Gen-Nifedipine XL), this tablet consists of a semipermeable membrane surrounding an osmotically active drug core. After contact with water from the GI tract osmotic pressure in the core increases, releasing the active drug at a controlled rate through an orifice in the tablet membrane. The functional principle of this nifedipine tablet seems to be quite similar to the one of the GITS system.

However, especially in case of modified release formulations, various factors can affect the absorption and the systemic availability of the drug. Two important factors are i) the drug release rate from the dosage form and ii) the gastrointestinal transit rate, which in turn has an influence on the site of absorption. Especially food intake and the caloric content of a meal can affect drug transit time, luminal dissolution and drug permeability. Thus, the prandial state may have a significant impact on the in vivo behaviour of such formulations as a whole and particularly on the drug bioavailability.

For GITS formulations, such as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, earlier studies have demonstrated that no significant influence of concomitant food-intake occurs.
Study Started
Apr 30
2009
Primary Completion
Apr 30
2009
Study Completion
Apr 30
2009
Last Update
Oct 21
2009
Estimate

Drug Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)

60 mg nifedipine

  • Other names: Nifedipine 60 mg, GITS

Drug Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)

60 mg nifedipine

1 Active Comparator

One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state

2 Active Comparator

One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state

3 Active Comparator

One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state

4 Active Comparator

One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state

Criteria 

Inclusion Criteria:

sex: male
ethnic origin: Caucasian
age: 18 - 55 years, inclusive
body-mass index (BMI): ³ 22 kg/m² and £ 27 kg/m²
good state of health (no clinically significant deviations from normal clinical results and laboratory findings)
the subject must give written informed consent, after having been informed about benefits and potential risks of the trial, as well as details of the insurance taken out to cover the subject's participating in the study

Exclusion Criteria:

existing cardiac or haematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics
existing hepatic and/or renal diseases and/or pathological findings, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics
existing gastrointestinal diseases and/or pathological findings, including severe gastrointestinal or esophageal constriction or narrowing, which might interfere with the drug's safety, tolerability, absorption and/or pharmacokinetics
history of relevant CNS and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
relevant pathological changes in the ECG (12 standard leads) such as a second- or third-degree AV block, complete bundle branch block, prolongation of the QRS complex over 120 msec or the QTc-interval above 450 msec
known allergic or intolerance reactions to the active ingredient used or to constituents of the pharmaceutical preparations (e.g. lactose intolerance)
subjects with severe allergies or multiple drug allergies
systolic blood pressure below 110 mmHg or above 155 mmHg
diastolic blood pressure below 60 mmHg or above 95 mmHg
resting heart rate in the awake subject below 45 bpm or above 90 bpm
laboratory values out of normal range unless the deviation from normal is judged as not relevant for the study by the investigator
positive anti-HIV-test, HBs-AG-test or anti-HCV-test Lack of suitability for the trial
acute or chronic diseases which could affect absorption or metabolism
history of or current drug or alcohol dependence
regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol per day
subjects who are on a diet which could affect the pharmacokinetics of the drug
regular intake of caffeine containing food or beverages of ≥ 500 mg (calculated as caffeine) per day
heavy smokers (≥ 10 cigarettes per day or equivalents of other nicotine containing products)
blood donation or other blood loss of more than 400 ml within the last two months prior to the start of the study
participation in a clinical trial during the last two months prior to individual enrolment of the subject
regular treatment with any systemically available medication (except hormonal replacement therapy e.g. L-thyroxine)
subjects, who report a frequent occurrence of migraine attacks Administrative reasons
subjects suspected or known not to follow instructions
subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study -
No Results Posted